Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20616140 | 1.00 | EPHX2 (0.41) | EPHX2ALDH1A1HTTSMN1; SMN2ACACB | |
| SCHEMBL21863862 | 1.00 | EPHX2 (0.41) | EPHX2ALDH1A1HTTSMN1; SMN2ACACB | |
| SCHEMBL2474297 | 0.90 | EPHX2 (0.48) | EPHX2ACACBFFAR4DGAT1SOAT1 | |
| SCHEMBL2474293 | 0.90 | EPHX2 (0.48) | EPHX2ACACBFFAR4DGAT1SOAT1 | |
| SCHEMBL21839163 | 0.85 | ACSL1 (0.41) | EPHX2FFAR4DGAT1SOAT1 | |
| SCHEMBL28897631 | 0.85 | ACSL1 (0.41) | EPHX2FFAR4DGAT1SOAT1 | |
| SCHEMBL21838823 | 0.85 | ACSL1 (0.41) | EPHX2FFAR4DGAT1SOAT1 | |
| SCHEMBL30663064 | 0.80 | SLC6A4 (0.49) | EPHX2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2471996 | 0.79 | EPHX2 (0.56) | EPHX2DGAT1SOAT1 | |
| SCHEMBL2471998 | 0.79 | EPHX2 (0.56) | EPHX2DGAT1SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11142527-B2 | Dihydropyrimidine compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| US-20200115381-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE | NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED (CN) | 2020-04-16 | — | — | US | disclosed |
| WO-2019001396-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115381-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE | DPYD, SLC10A1, DHODH | EPHX2 1617/4885ALDH1A1 798/4885HTT 334/4885 |
| US-11142527-B2 | Dihydropyrimidine compounds and uses thereof in medicine | DPYD, SLC10A1, DHODH | EPHX2 1617/4885ALDH1A1 798/4885HTT 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.